

Sandoz Pharma S.A.E Provides Cardiac Patients with Treatment at Affordable Price

Sandoz Egypt Pharma held a conference to announce the availability of a drug containing Clopidogrel, used for the treatment of cardiovascular disease in Egypt. "This is the first time a generic drug of this kind compliant with international standards is introduced to the Egyptian market. It has been proven and approved to be Bioequivalent to the original drug, and Sandoz Pharmaceuticals, one of Novartis Divisions, has managed to release a drug containing Clopidogrel to the public for less than half of the original product price in Egypt," said Dr. Sameh Shaheen, Professor of Cardiology at Ain Sharms University and former President of the Egyptian Society of Cardiology.